-
Mashup Score: 10BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report - 2 year(s) ago
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of all ovarian carcinomas. HGSOC harboring BRCA1/2 germline or somatic mutations are sensitive to the poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi). Therefore, detecting these mutations is crucial to identifying patients for PARPi-targeted treatment. In the clinical setting, next generation sequencing (NGS)…
Source: MDPICategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
An experimental antiviral pill from Pfizer reduced Covid patients’ risk of death and hospitalization by 89% in a large study.
Source: STATCategories: Latest Headlines, Oncologists2Tweet-
RT @VivekSubbiah: ⭐️🚨Experimental Pfizer pill prevents Covid hospitalizations and deaths https://t.co/n9D7fMGzr4 via @statnews
-
-
Mashup Score: 9In Gratitude for mRNA Vaccines | NEJM - 3 year(s) ago
Clinical Implications of Basic Research from The New England Journal of Medicine — In Gratitude for mRNA Vaccines
Source: New England Journal of MedicineCategories: Latest Headlines, Oncologists2Tweet-
RT @VivekSubbiah: In Gratitude for mRNA Vaccines | NEJM @NEJM https://t.co/jnzMn4DqtZ
-
-
Mashup Score: 11Molecular profiling of advanced solid tumours.... - 3 year(s) ago
Molecular-matched therapies have revolutionized cancer treatment. We evaluated the improvement in clinical outcomes of applying an in-house customized Next Generation Sequencing panel in a single institution. Patients with advanced solid tumors were molecularly selected to receive a molecular-matched treatment into early phase clinical trials versus best investigators choice, according to the…
Source: www.nature.comCategories: Latest Headlines, Oncologists2Tweet-
RT @AndresC27622123: Proud of my team publishing this article in @BrJCancer: https://t.co/wGtQVjJKxV. Molecular profiling of advanced solid…
-
-
Mashup Score: 2FirstWord Pharma - 3 year(s) agoSource: new.firstwordpharma.comCategories: Latest Headlines, Oncologists2Tweet
-
RT @curijoey: AstraZeneca, Daiichi Sankyo's Enhertu tops Kadcyla in breast cancer study https://t.co/zcoy8ydFML via @fwpharma
-
-
Mashup Score: 10Trends in kinase drug discovery: targets, indications and inhibitor design - Nature Reviews Drug Discovery - 3 year(s) ago
The FDA approval of imatinib in 2001 heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. This article analyses the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of kinase inhibitors, their expanding range of indications and strategies for kinase inhibitor design.
Source: Nature Reviews Drug DiscoveryCategories: Latest Headlines, Oncologists2Tweet-
20 years of Drug Development! The current landscape of approved & investigational therapies that targets kinases. A great list of kinase inhibitors & ↗️range of indications. #egfr #clinicaltrials #kinases #ret #met #cdk4_6 #lcsm #kcsm #bcsm @NatRevDrugDisc https://t.co/z2WMxe6WGk https://t.co/tZ5KgMoXby
-
-
Mashup Score: 3Advancing Global Cancer Care Innovations Accelerated by the COVID-19 Pandemic: A Conversation With 2021-2022 ASCO President Dr. Everett E. Vokes - 3 year(s) ago
Dr. Vokes is dedicating his tenure as 2021-2022 ASCO president to expanding ASCO’s global reach and advancing lessons learned from the COVID-19 pandemic to improve cancer care for all patients.
Source: ASCO ConnectionCategories: Latest Headlines, Oncologists2Tweet-
RT @jrgralow: .@ASCOPres Everett Vokes discusses his goals and his @asco presidential theme https://t.co/cLb9Uh57p5
-
-
Mashup Score: 7Epigenetic checkpoint blockade: new booster for immunotherapy - Signal Transduction and Targeted Therapy - 3 year(s) ago
Signal Transduction and Targeted Therapy –
Epigenetic checkpoint blockade: new booster for… Categories: Latest Headlines, Oncologists2Tweet-
RT @AndresFCardonaZ: Epigenetic checkpoint blockade: new booster for immunotherapy https://t.co/IH61yZa5qV
-
-
Mashup Score: 14‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer - 3 year(s) ago
Triple-negative breast cancer (TNBC) comprises a heterogenous group of breast cancers, with an extremely poor prognosis in patients with metastatic disease. Important advancements have been made in the treatment landscape for TNBC, with most notably the approval of first-line treatment with nanoparticle albumin-bound (nab)-paclitaxel and atezolizumab for patients with programmed death-ligand 1…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @lab_kok: 👇 Our editorial regarding IMpassion130 and 131 landmark studies in Ann Oncol @Annals_Oncology #bcsm https://t.co/eWrghqMY2O
-
-
Mashup Score: 1Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression - Nature Cancer - 3 year(s) ago
Drake and colleagues demonstrate that castration in prostate cancer models promotes IL-8 secretion and immunosuppressive myeloid-derived suppressor cell migration, and that inhibiting this axis in combination with checkpoint blockade can mitigate tumor progression.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @charles_ferte: Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression https://t.co/IecrwyQhpz
-
RT @UmbertoMalapel1: #BRCA somatic gene testing in #RealWorld practice! @MDPIOpenAccess https://t.co/ngr9VpyrsU https://t.co/9wYjuJFi3m